<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852021000100005</article-id>
<article-id pub-id-type="doi">10.48193/revistamexicanadeurologa.v81i1.707</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Impacto de la prostatectomía radical y la radioterapia en la calidad de vida de pacientes con cáncer de próstata clínicamente localizado]]></article-title>
<article-title xml:lang="en"><![CDATA[Impact of radical prostatectomy and radiotherapy on the quality of life of patients with localized prostate cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sáiz-Marencoa]]></surname>
<given-names><![CDATA[Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campanario-Péreza]]></surname>
<given-names><![CDATA[Rubén]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amores-Bermúdeza]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arroyo-Maestrea]]></surname>
<given-names><![CDATA[José Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Juárez-Soto]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario de Jerez de la Frontera  ]]></institution>
<addr-line><![CDATA[Jerez de la Frontera Cádiz]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<volume>81</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852021000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852021000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852021000100005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivos: La evaluación de la calidad de vida asociada a distintos tratamientos en pacientes con cáncer de próstata es clave para tomar decisiones terapéuticas informadas. Sin embargo, los resultados en práctica clínica son heterogéneos e insuficientes.  Material y métodos: Estudio observacional prospectivo en pacientes que iban a iniciar tratamiento con radioterapia externa o prostatectomía radical laparoscópica (PR) por cáncer de próstata localizado. Se completó el cuestionario de calidad de vida EPIC-CP antes de iniciar el tratamiento (basal) y tras 6, 12 y 24 meses del tratamiento.  Resultados: El análisis incluyó 59 pacientes: 34 (58%) se sometieron a prostatectomía radical y 25 (42%) recibieron radioterapia. La calidad de vida media empeoró en los dos grupos de tratamiento y para todos los dominios, observándose un empeoramiento máximo a los 6 meses, recuperándose hasta normalizar las puntuaciones a los 24 meses. A los 6 y 12 meses de tratamiento, el porcentaje de pacientes que experimentó un cambio mínimo relevante en calidad de vida fue significativamente superior en el grupo de PR que en el de radioterapia para los dominios incontinencia y sexual; estas diferencias no se observaron a los 24 meses.  Discusión: El cuestionario EPIC-CP permite estimar el cambio mínimo relevante, facilitando así la interpretación clínica de los resultados.  Conclusiones: A medio plazo, la PR y la radioterapia externa impactan de una forma distinta en la calidad de vida asociada a la incontinencia y la función sexual. A los 24 meses del tratamiento la calidad de vida se normaliza, independiente del tratamiento elegido.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objectives: The evaluation of quality of life associated with different treatments in patients with prostate cancer is a key factor in making informed therapeutic decisions. Nevertheless, results in clinical practice are heterogeneous and insufficient.  Material and methods: A prospective, observational study was conducted on patients that were going to begin treatment with external beam radiotherapy or laparoscopic radical prostatectomy (LPR) due to localized prostate cancer. The EPIC-CP quality of life questionnaire was completed before starting treatment (baseline) and then 6, 12, and 24 months after treatment.  Results: Fifty-nine patients were included in the analysis: 34 (58%) underwent radical prostatectomy and 25 (42%) received radiotherapy. Mean quality of life worsened in the two treatment groups and in all the domains. Maximum decline was at 6 months, and normal scores were recovered at 24 months. At months 6 and 12 after treatment, the percentage of patients that experienced a minimal important difference in quality of life was significantly higher in the LPR group than in the radiotherapy group for the incontinence and sexual function domains. There was no difference between the two groups at 24 months.  Discussion: Minimal important difference could be calculated using the EPIC-CP questionnaire, thus facilitating the clinical interpretation of the results.  Conclusions: At the medium term, LPR and radiotherapy had a different impact on the quality of life associated with incontinence and sexual function. At 24 months after treatment, quality of life was restored, regardless of treatment.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Health-related quality of life]]></kwd>
<kwd lng="en"><![CDATA[Prostate cancer]]></kwd>
<kwd lng="en"><![CDATA[Radical prostatectomy]]></kwd>
<kwd lng="en"><![CDATA[External beam radiotherapy]]></kwd>
<kwd lng="en"><![CDATA[EPIC-CP]]></kwd>
<kwd lng="es"><![CDATA[Calidad de vida asociada a la salud]]></kwd>
<kwd lng="es"><![CDATA[Cáncer de próstata]]></kwd>
<kwd lng="es"><![CDATA[Prostatectomía radical]]></kwd>
<kwd lng="es"><![CDATA[Radioterapia externa]]></kwd>
<kwd lng="es"><![CDATA[EPIC-CP]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Global Cancer Observatory]]></source>
<year>2019</year>
<publisher-name><![CDATA[International Agency for Research on Cancer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Sociedad Española de Oncología Médica</collab>
<source><![CDATA[Cifras del cáncer en España | SEOM - Día Mundial del Cáncer 2020]]></source>
<year>2020</year>
<publisher-name><![CDATA[Sociedad Española de Oncología Médica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Ministerio de Sanidad y Consumo</collab>
<source><![CDATA[Guía de Práctica Clínica sobre Tratamiento de Cáncer de Próstata]]></source>
<year>2008</year>
<publisher-name><![CDATA[Instituto Aragonés de Ciencias de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mottet]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cornford]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bergh]]></surname>
<given-names><![CDATA[R van den]]></given-names>
</name>
<name>
<surname><![CDATA[Briers]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fanti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Prostate Cancer]]></source>
<year>2019</year>
<publisher-name><![CDATA[EUA Guidelines]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lardas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liew]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van den Bergh]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bellmunt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Van den Broeck]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2017</year>
<volume>72</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>869-85</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Szymanski]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Chipman]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Litwin]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2011</year>
<volume>186</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>865-72</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Haji]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ismail]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Brundage]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) tool: Acceptability, feasibility and potential role in enhancing clinical care of men with early-stage prostate cancer]]></article-title>
<source><![CDATA[JCO]]></source>
<year>2016</year>
<volume>34</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>e21631</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chipman]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sanda]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Litwin]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Crociani]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2014</year>
<volume>191</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>638-45</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skolarus]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Sanda]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Greenfield]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Litwin]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2015</year>
<volume>85</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>101-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gandaglia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tilki]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zaffuto]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fossati]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pompe]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Dell&#8217;Oglio]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions]]></article-title>
<source><![CDATA[European Urology Focus]]></source>
<year>2019</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>545-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Bowie]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Thorpe]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kinlock]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Burt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors Associated with Men&#8217;s Assessment of Prostate Cancer Treatment Choice]]></article-title>
<source><![CDATA[J Cancer Educ]]></source>
<year>2016</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>301-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Stam]]></surname>
<given-names><![CDATA[M-A]]></given-names>
</name>
<name>
<surname><![CDATA[Aaronson]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[JLHR]]></given-names>
</name>
<name>
<surname><![CDATA[Kieffer]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[van der Voort van Zyp]]></surname>
<given-names><![CDATA[JRN]]></given-names>
</name>
<name>
<surname><![CDATA[Tillier]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices]]></article-title>
<source><![CDATA[Eur Urol Oncol]]></source>
<year>2020</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-31</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D&#8217;Amico]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Whittington]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Malkowicz]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Fondurulia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1999</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>168-72</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hatzimouratidis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Giuliano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Moncada]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Muneer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Salonia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Verze]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Male sexual dysfunction]]></source>
<year>2018</year>
<publisher-name><![CDATA[EUA Guidelines]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balbontin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Marchetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cabello]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Urzúa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calidad de vida en pacientes con cáncer de próstata: Validación de un instrumento para la práctica clínica]]></article-title>
<source><![CDATA[Archivos Españoles de Urología]]></source>
<year>2015</year>
<volume>68</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>466-73</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donovan]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Hamdy]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Metcalfe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1425-37</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanda]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Michalski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sandler]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Northouse]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hembroff]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life and satisfaction with outcome among prostate-cancer survivors]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>358</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1250-61</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bacon]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Giovannucci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Testa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kawachi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2001</year>
<volume>166</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1804-10</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Guedea]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Aguiló]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Macías]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mariño]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2010</year>
<volume>28</volume>
<numero>31</numero>
<issue>31</issue>
<page-range>4687-96</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
